Amphoraxe Life Sciences lands C$892k Canadian grant for poultry antibiotic alternatives
What's the deal? Amphoraxe Life SciencesDealroom has a profile for this one. Try Dealroom → has secured up to C$892,122 (≈$626,970) from the Government of CanadaDealroom has a profile for this one. Try Dealroom → to develop antibiotic alternatives for poultry farming.
The grant, awarded through the AgriScience Program, will fund antimicrobial peptide technology designed to fight harmful bacteria in poultry operations.
Targets include Avian pathogenic E. coli and Salmonella enterica, two common threats to flock health.
Amphoraxe will develop and test up to 10 peptide formulations, produced using sustainable methods and screened for safety and efficacy.
The project draws on the Provincial Health Services Authority and the University of Victoria, combining genomics, artificial intelligence, and peptide engineering.
Why now? Antimicrobial resistance is a growing concern for livestock producers worldwide, as disease-causing bacteria become less responsive to conventional treatments.
The funding falls under the Sustainable Canadian Agricultural Partnership, a five-year framework aimed at boosting the competitiveness and resilience of Canadian agriculture.
What could go wrong? Peptide-based solutions remain experimental, and the project must prove its formulations are both safe and effective before they can reach farms.
Producers also face evolving regulatory and consumer expectations that any new product will need to satisfy.
The signal: The grant is an early-stage bet on a company whose entire pitch — AI-powered antimicrobial peptides for both veterinary and human use — is built around the antimicrobial resistance problem this funding targets. As a government and non-profit backer, the Government of Canada is using non-dilutive funding to push lab research toward the kind of exportable life sciences technology the country is keen to commercialise.
Image credit: woodleywonderworks
